FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype

Leukemia Research

Volumn 28, Issue 6, 2004, Pages 547-550

  Beran, Miloslav ^a   Luthra, Rajyalakshmi ^a   Kantarjian, Hagop ^a   Estey, Elihu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Age; Chemotherapy outcome; Diploid AML; Flt3 mutation

Indexed keywords

ARABINOSIDE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FLT3 LIGAND; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 11; RETINOIC ACID; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SURVIVAL; CONTROLLED STUDY; DIPLOIDY; DISEASE RESISTANCE; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TANDEM REPEAT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DIPLOIDY; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REMISSION INDUCTION; SURVIVAL RATE; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME;

EID: 2142675553     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.09.016     Document Type: Article

References (13)

1. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood. 100:2002;1532-1542
2. Meshinchi S., Woods W.G., Stirewalt D.L., Sweetser D.A., Buckley J.D., Tjoa T.K., et al. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myelogenous leukemis. Blood. 97:2001;89-94
3. Kiyoi H., Naoe T., Nakano Y., Yokota S., Minami S., Miyawaki S., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 93:1999;3074-3080
4. Rombouts W.J., Blokland I., Lowenberg B., Ploemacher R.E. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 14:2000;675-683
5. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Gari M.A., Peake I.R., Rees D.C., et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. 111:2000;190-195
6. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 98:2001;1752-1759
7. Stirewalt D.L., Kopecky K.J., Meshinchi S., Appelbaum F.R., Slovak M.L., Willman C.L., et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 97:2001;3589-3595
8. Whitman S.P., Archer K.J., Feng L., Baldus C., Becknell B., Carlson B.D., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 61:2001;7233-7239
9. Frohling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., et al. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 100:2002;4372-4380
10. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., et al. Activating mutation of D835 within the activating loop of FLT3 in human hematologic malignancies. Blood. 97:2001;2434-2439
11. Boissel N., Cayuela J.M., Fund X., Raffoux E., Taksin A.L., Rousselot P., et al. Double induction in acute myelogenous leukemia (AML) with FLT3 gene internal tandem duplication [abstract]. Blood. 96:2000;316
12. Estey E.H., Thall P.F., Cortes J.E., Giles F.J., O'Brien S., Pierce S.A., et al. Comparison of idarubicin + ara-C-fludarabine + ara-C- and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 98:2001;3575-3583
13. Beran M., Shen Y., Kantarjian H., O'Brien S., Koller C.A., Giles F.J., et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer. 92(8):2001;1999-2015